JPRN-UMIN000028166招募中未知
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib - Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib (ALCSG-04)
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients are excluded if they have; 1. Severe concomitant disease. 2. Severe history oh hypersensitivity. 3. Severe heart disease or arrhythmia. 4. Interstitial pneumoniae. 5. Active infection. 6. Active peptic ulcer. 7. Active double cancer. 8. Symptomatic brain metastasis.
研究者
相似试验
已完成
不适用
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerPatients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerJPRN-UMIN000027655Division of Thoracic Oncology, Shizuoka cancer center18
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
已完成
2 期
E-LiquidJPRN-jRCT2080225059Department of Thoracic Oncology, National Cancer Center Hospital East91
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54